X4 Pharmaceuticals Reports $8.8 Million Revenue for Q2 2026, Net Loss Improves

X4 Pharmaceuticals, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated total revenue of $8.8 million for the quarter, a substantial increase from $2.0 million in the same period last year. This growth was driven by a rise in product revenue, which reached $2.4 million compared to $1.7 million in the prior year, and license revenue of $6.4 million, primarily from a regulatory milestone achieved under its agreement with Norgine Pharma UK Ltd. For the first half of 2026, total revenue was $11.5 million, down from $30.8 million in the same period of 2025, largely due to a significant one-time revenue recognition in the previous year.

The company reported a net loss of $16.2 million for the second quarter, an improvement from a net loss of $25.7 million in the same quarter of 2025. For the first half of 2026, the net loss was $36.4 million, compared to $25.5 million in the prior year. The reduction in losses was attributed to decreased operating expenses, which fell to $25.2 million from $28.2 million year-over-year, driven by lower research and development costs following strategic restructuring efforts that reduced employee headcount by approximately 65%.

Operationally, X4 Pharmaceuticals continues to focus on its lead product, XOLREMDI (mavorixafor), which has received accelerated approval from the FDA for treating patients with WHIM syndrome. The company is also advancing its pivotal Phase 3 clinical trial, known as the 4WARD trial, for mavorixafor in patients with chronic neutropenia. The company has transitioned management of this trial to a specialized Clinical Research Organization to enhance execution and support enrollment completion. Additionally, X4 has expanded its geographic reach with the recent marketing authorization granted by the European Commission for XOLREMDI.

As of June 30, 2026, X4 Pharmaceuticals had cash, cash equivalents, and marketable securities totaling $195.8 million, down from $217.9 million at the end of 2025. The company anticipates that its current financial resources will be sufficient to fund operations and meet obligations for at least the next 12 months. However, it acknowledges the need for additional capital to support ongoing research and development efforts, particularly as it continues to incur operating losses. The company is exploring various funding avenues, including equity offerings and collaborations, to ensure it can sustain its operations and advance its product pipeline.